Q32 Bio to Participate in Upcoming March Investor Conferences
Q32 Bio (Nasdaq: QTTB), a clinical stage biotechnology company specializing in immune homeostasis therapeutics, has announced its participation in two major investor conferences this March.
The company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025, at 11:50 a.m. ET, followed by the Leerink Partners Global Healthcare Conference in Miami Beach on March 11, 2025, at 11:20 a.m. ET.
Webcasts of both presentations will be accessible through Q32 Bio's website, with replays available for 90 days after the events.
Q32 Bio (Nasdaq: QTTB), una società biotecnologica in fase clinica specializzata in terapie per l'omeostasi immunitaria, ha annunciato la sua partecipazione a due importanti conferenze per investitori questo marzo.
La società presenterà alla TD Cowen 45ª Conferenza Annuale sulla Salute a Boston il 5 marzo 2025, alle 11:50 ET, seguita dalla Leerink Partners Global Healthcare Conference a Miami Beach l'11 marzo 2025, alle 11:20 ET.
I webcast di entrambe le presentazioni saranno accessibili attraverso il sito web di Q32 Bio, con repliche disponibili per 90 giorni dopo gli eventi.
Q32 Bio (Nasdaq: QTTB), una empresa de biotecnología en etapa clínica especializada en terapias para la homeostasis inmune, ha anunciado su participación en dos importantes conferencias para inversores este marzo.
La empresa presentará en la 45ª Conferencia Anual de Atención Médica de TD Cowen en Boston el 5 de marzo de 2025, a las 11:50 a.m. ET, seguida de la Conferencia Global de Atención Médica de Leerink Partners en Miami Beach el 11 de marzo de 2025, a las 11:20 a.m. ET.
Las transmisiones en vivo de ambas presentaciones estarán disponibles a través del sitio web de Q32 Bio, con repeticiones disponibles durante 90 días después de los eventos.
Q32 Bio (Nasdaq: QTTB)는 면역 항상성 치료제를 전문으로 하는 임상 단계의 생명공학 회사로, 이번 3월에 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 2025년 3월 5일 오전 11시 50분 ET에 보스턴에서 열리는 TD Cowen 제45회 연례 건강 관리 회의에서 발표하며, 이어서 2025년 3월 11일 오전 11시 20분 ET에 마이애미 비치에서 열리는 Leerink Partners 글로벌 건강 관리 회의에서 발표할 예정입니다.
두 발표의 웹캐스트는 Q32 Bio의 웹사이트를 통해 접근할 수 있으며, 이벤트 후 90일 동안 다시 볼 수 있습니다.
Q32 Bio (Nasdaq: QTTB), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies de l'homéostasie immunitaire, a annoncé sa participation à deux grandes conférences pour investisseurs ce mois de mars.
L'entreprise présentera à la 45e Conférence Annuelle sur la Santé de TD Cowen à Boston le 5 mars 2025, à 11h50 ET, suivie de la Conférence Mondiale sur la Santé de Leerink Partners à Miami Beach le 11 mars 2025, à 11h20 ET.
Les webcasts des deux présentations seront accessibles via le site web de Q32 Bio, avec des rediffusions disponibles pendant 90 jours après les événements.
Q32 Bio (Nasdaq: QTTB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien zur Immunhomöostase spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März bekannt gegeben.
Das Unternehmen wird am 5. März 2025 um 11:50 Uhr ET auf der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston präsentieren, gefolgt von der Leerink Partners Global Healthcare Conference in Miami Beach am 11. März 2025 um 11:20 Uhr ET.
Webcasts beider Präsentationen werden über die Website von Q32 Bio zugänglich sein, mit Wiederholungen, die 90 Tage nach den Veranstaltungen verfügbar sind.
- None.
- None.
TD Cowen 45th Annual Health Care Conference
Date: Wednesday, March 5, 2025
Presentation Time: 11:50 a.m. E.T.
Location:
Leerink Partners Global Healthcare Conference
Date: Tuesday, March 11, 2025
Fireside Chat Presentation Time: 11:20 a.m. E.T.
Location:
A webcast of the presentations will be available on the Events and Presentations page of Q32 Bio's website at www.Q32Bio.com. Archived replays will be available for 90 days following the event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases.
Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases being evaluated in a Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our investors and the public using our company website www.Q32Bio.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Contacts:
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-upcoming-march-investor-conferences-302385199.html
SOURCE Q32 Bio
FAQ
When and where will Q32 Bio (QTTB) present at the TD Cowen Healthcare Conference in March 2025?
What is the schedule for Q32 Bio's (QTTB) presentation at the Leerink Partners Conference?
How long will Q32 Bio's (QTTB) March 2025 conference presentations be available for replay?
Where can investors access Q32 Bio's (QTTB) March 2025 conference presentations?
